Sector News

FDA opens door to multiarm, multicompany clinical trials

December 7, 2017
Life sciences

The FDA has outlined how developers of drugs targeting rare pediatric diseases can streamline their clinical development programs by collaborating. Officials want drug developers to consider teaming up to test multiple candidates in single trials, thereby cutting the number of patients who need to receive placebos.

Using Gaucher disease as an example, the FDA’s draft guidance (PDF) shows how companies can team up and run multidrug clinical trials. These studies would enable multiple experimental candidates to be compared against a single control group, increasing the proportion of patients in active arms.

Other sections of the guidance propose the use of modeling and simulation to predict the effect of a drug in children based on prior performance in adults. Collectively, the FDA sees the proposals streamlining the development of drugs to treat rare pediatric diseases.

“The FDA has drafted an approach to pediatric rare disease drug development that could eliminate the need for certain clinical studies and, when pediatric clinical studies are needed, could reduce the total number of patients who would receive a placebo instead of a potentially helpful drug,” Janet Woodcock, M.D., director of the FDA’s Center for Drug Evaluation and Research, said in a statement.

The genesis of the document dates back to 2011, when the FDA began working with the European Medicines Agency (EMA) to create a roadmap for the development of Gaucher disease drugs. That resulted in a guidance document that was released for public comment in 2014 and adopted (PDF) by the EMA earlier this year. It has now led to the publication of the draft FDA guidance.

Woodcock and her colleagues have copied large sections of the Gaucher guidance word for word but have extended its scope beyond the condition. In its new form, the FDA guidance proposes extending the principles underpinning the Gaucher development model to other diseases.

The guidance is still in a draft form and is open for comment for 60 days.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

January 15, 2022

Colorcon Ventures invests in AI-Driven bio-simulation company VeriSIM Life

Life sciences

Colorcon Ventures, the corporate venture fund of Colorcon Inc., has invested in VeriSIM Life, a San Francisco-based startup with a digital bio-simulation platform that accelerates drug development and reduces animal testing.

January 15, 2022

A record number of biotechs are going public. Here’s how they’re performing.

Life sciences

Initial public offerings have fueled biotech’s boom. Keep track of them as they happen with this database. Which biotechs create value over time, and which fail? What types of companies are generating the best returns? Who are their top investors? Biopharma Dive is tracking these details in the database which will be updated regularly.

January 15, 2022

Sanofi cuts ties with Sangamo, sharpening focus on ‘off-the-shelf’ cell therapy

Life sciences

Sanofi has ended a long-running alliance with Sangamo Therapeutics to develop genetic medicines for inherited blood disorders, among them an experimental sickle cell disease therapy that is in early clinical testing.
The two have been developing complex, personalized treatments, led by a sickle cell drug known as SAR445136. But Sanofi is now more interested in off-the-shelf approaches, which are meant to be more convenient.

Send this to a friend